Cudarolimab 产品活性：Cudarolimab (IBI101) 是一种完全人抗 OX40 (CD134，一种由激活的免疫细胞表达的共刺激分子) 抗体。Cudarolimab 抑制 OX40 与其配体 OX40L 的结合。Cudarolimab 具有抗肿瘤活性，可用于癌症相关研究。 产品来源： https://www.medchemexpress.cn/cudarolimab.html 研究领域：GPCR/G Protein | Neuronal Signaling 作用靶点：Orexin Receptor (OX Receptor) In Vitro: Cudarolimab (0.01, 1, 100 or 10000 nM) binds to OX40 and partially blocks the binding of OX40 to its ligand OX40L in CHO-S cells overexpressing human OX40 (CHO-S-hOX40). Cudarolimab activates OX40 dependent NF-κB reporters with an EC50 value of 4.432 nM in Jurkat-OX40 reporter cells co-cultured with Raji cells. Cudarolimab (0.01, 0.1, 1, 10, 100 or 1000 nM) binds to activated human CD4+ T cells and activated cynomolgus monkey CD4+ T cells in a dose dependent manner. Cudarolimab (0.4, 4.0 and 40.4 nM) increases IL-2 secretion with dose dependent manner in human CD4+ T cells. In Vivo: Cudarolimab (10 mg/kg; i.p.; single dose on days 3, 7, 11, 14 and 15) significantly reduces tumor volume in humanized NOG mice bearing LoVo tumors. Cudarolimab (0.1, 1 and 10 mg/kg; i.p.; single dose on days 6, 9, 12 and 16) significantly reduces tumor volume, increases IFN-γ+ and IFN-α+ expression in CD8+ T cells in tumor and spleen of human OX40 knock-in mice bearing MC38 tumors. Cudarolimab (10 mg/kg; i.p.; single dose on days 10 and 14) significantly reduces the expression of CD3+CD8+, CD3+CD4+, CD4+CD25highFoxP3+ in the tumor and spleen of human OX40 knock-in mice bearing MC38 tumors. Pharmacokinetic (PK) parameters of Cudarolimab in cynomolgus macaques Dose (mg/kg) Cmax (µg/mL ) Tmax (h) AUC0-∞ (h•µg/mL ) T1/2 (h) Cl (mL/h/kg) MRTlast (h) 0.1 3.07±0.40 0.08±0.00 347.98±99.30 162.98±103.01 0.31±0.08 186.34±110.68 0.5 9.78±3.27 0.40±0.78 1429.19±607.21 129.47±114.44 0.40±0.14 136.03±108.05 2.5 63.10±15.29 0.08±0.00 10304.06±3403.59 190.89±92.94 0.27±0.09 212.29±114.61 12.5 296.57±58.05 0.40±0.78 33511.65±14982.36 120.30±153.26 0.44±0.20 114.93±87.66 相关产品：Orexin A (human, rat, mouse) (TFA) | Danavorexton | Almorexant | SB-334867 free base | YNT-185 dihydrochloride | Seltorexant | EMPA | JNJ-10397049 | Orexin 2 Receptor Agonist | SB-674042 | Filorexant | Orexin B, human TFA | SB-649868 | MK-1064 | OXA(17-33) | TCS 1102 | TCS-OX2-29 | ACT-462206 | GSK1059865 | Revdofilimab | Firazorexton | Orexin B, rat, mouse | RTIOXA-43 | SB-408124 | Vornorexant 品牌介绍: MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供最新最全的高品质小分子活性化合物；10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；设有专业的实验中心和严格的质控、验证体系；提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；产品的生物活性多经各国客户实验验证；Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；与世界各大制药公司及知名科研机构建立了长期的合作。